halt and get ready for the next chapter

Interestering articles found by Shaynolano reproduced below


New patent application 07/04/2011

Head inventor ? cbios head of intellectual property development
25. A method for treating or preventing a disease, disorder or condition in a subject, the method comprising administering to the subject an effective amount of a polypeptide according to claim 1 either alone or in combination with at least one nucleic acid based PRR ligand, a nucleic acid according to claim 18, or any combination thereof.

26. The method of claim 25, wherein said disease, disorder or condition is selected from: acute or chronic inflammatory diseases such as, insulin dependent diabetes mellitus, systemic lupus erythematosis, Sjorgren's disease, Graves disease, multiple sclerosis, rheumatoid arthritis, chronic fatigue syndrome, Alzheimer's disease, asthma, allergy, GVHD, artherosclerosis, inflammatory pain, psoriasis, HIV, Chronic immune activation, chronic myositis, scleroderma; or cancers such as, non-small cell lung carcinoma, renal cell carcinoma, melanoma, non-Hodgkin's lymphoma, colorectal cancer, basal cell carcinoma; or an infectious disease

This indicates that most of the Cpn10 mutants have the ability to modulate the immune system, particularly, when involving TLR3 signalling.
Read more: http://www.faqs.org/patents/app/20110082073#ixzz1JMxxkGx9

What I read is that this means is that they have discovered that they can add charge or take charge from cpn10 (with amino acids) to modify its properties and have increased effect on auto immune disease. I particularly liked the list of diseases they listed as possibilities for treatment ? note ? HIV?Alzheimers?

ALSO
Taiwan prepares to develop biotechnology sector

Du Hui-rong and Staff Reporter 2011-05-02 19:19 (GMT+8)

Taiwan's biomedical industry has government backing, plans overseas listings and sales and is also attracting foreign biomedical companies to list in Taiwan. Picture: A pharmacist prepares a prescription. (File Photo/China Times)

Thanks to the support of President Ma Ying-jeou and Vice President Vincent Siew, Taiwan will take its first step towards developing the biotechnology sector once the government approves the first biotech venture capital firm. The approval is expected soon, according to sources.

As a next step, Christina Liu, minister of the Council for Economic Planning and Development, and Cyrus Chu, minister without portfolio, will visit the United States to solicit investment in the industry later this month and in June, respectively.

Owing to the brisk growth of biotech shares in Taiwan, well-known pharmaceutical companies such as US-based Epitomics are planning stock market listings in Taiwan. Australia's CBIO also plans to issue depositary receipts in Taiwan.

Several US biotech firms launched by Taiwanese Americans are also cooperating with their local counterparts to explore the island's market.

Optimer Pharmaceuticals, jointly established by Wang Chi-huey, president of Academica Sinica, and Michael Chang, has launched Ptimer Biotechnology Inc in Taiwan to sell its patented antibiotic drug DIFICIDMT (Fidaxomicin) in Taiwan from the second half of 2012. The drug received approval for sale in the United States recently.

The company predicted that the drug, the only one developed from the start by Taiwanese scientists, would create a market worth US$400-500 million a year on the island.

In addition to selling in the United States, China and Taiwan, Optimer authorized Japanese firm Astellas in February to sell the drug in Europe in exchange for a royalty fee of US$224 million.

Meanwhile, the Polaris Group, owned by Taiwanese foodstuff manufacturer Hsin Tung Yang, reported significant progress in developing a liver cancer drug codenamed ADI-PEG 20. Company chairman Wu Bor-wen also announced that Polaris would list on the US stock market to raise US$70-100 million.

Taiwan's efforts to promote the biotechnology industry as well as its production of medical instruments, including blood-pressure meters and blood glucose meters, have caught the attention of international personalities in this field. Proof of this comes from the fact that William J Rutter, developer of vaccines for hepatitis B and C, will visit Taiwan for the first time to deliver a speech May 13.

Arthritis is only application-as I have posted previously-this could well be the Holy Grail of the auto immune system-CPN10 could well be the most valuable drug discovered by mankind.